Abstract: The cystic fibrosis gene and its gene product are described for both the normal and mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, drug and gene therapy, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.

Abstract: The cystic fibrosis gene and its gene product are described for both the normal and mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, drug and gene therapy, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.

Abstract: The cystic fibrosis gene and its gene product are described for both the normal and mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, drug and gene therapy, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.

Abstract: The cystic fibrosis gene and its gene product are described for both the normal and mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, drug and gene therapy, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.

Abstract: The identification, isolation and cloning of DNA sequences coding for mutant forms of the cystic fibrosis gene and their gene product are described. DNA sequence information and information relating to the genomic structure of the cystic fibrosis gene are provided. The mutant forms of the CF gene include specific sequence alterations in coding portions or of other genetic information at exon/intron boundaries and altered RNA transcripts and mutant protein products. Such DNA and protein information is useful in developing DNA or protein diagnosis for CF mutations, carrier and patient screening, as well as cloning of mutant genes and manufacturing of their proteins for investigation into therapies for cystic fibrosis.

Abstract: A process for transplanting into an immunodeficient mouse, which is deficient in T-cells and B-cells, human cells to form a chimeric mouse is provided. The transplanted human cells proliferate and thereby permit in vivo study of the human cells. The human cells are isolated from a human tissue source. The process comprises:i) irradiating an immunodeficient mouse deficient in T-cells and B-cells with radiation to condition the mouse for transplant:ii) transplanting into the irradiated mouse, the isolated human cells; andiii) maintaining the mouse to proliferate the human cells in and permit the human cells to spread in the mouse,to provide thereby a chimeric mouse incorporating the human cells in appropriate murine tissue.

Abstract: The cystic fibrosis gene and its gene product are described for mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.

Abstract: The cystic fibrosis gene and its gene product are described for both the normal and mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, drug and gene therapy, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.

Abstract: This invention relates to the identification of verocytotoxin receptors of the formula:X--O--Y(R) (I)wherein Y is sphingosine, hydroxylated sphinogosine or saturated sphingosine,wherein X is selected from said group and optionally a polysaccharide linking X to the --O--Y(R) group, andwherein R is H, or a fatty acid and R is linked to the amine moiety of the sphingosine,in combination with an assay component and their use in novel receptor-binding assays for the detection and quantitation of verocytotoxins.

Abstract: A time-resolved photographic analysis device is capable of analyzing for the presence of fluorescent radiation, particularly in a diagnostic sample. The apparatus comprises a light source for emitting exciting pulses as directed onto the sample. A camera is provided which is focused on the sample with the camera continually exposed to the sample. A chopper device is used in conjunction with the camera to prevent exposure of the photographic film in the camera to background fluorescence generated by miscellaneous components in the sample. Fluorescent labels, if present in the sample, are designed to fluoresce over considerably longer periods than the background fluorescence. A device is provided to coordinate the operation of the chopper device with the rate of flashing of the light source to ensure that the photographic film is only exposed to fluorescent radiation which would be generated by a fluorescent label in the sample being analyzed.

Abstract: A double lumen flexible catheter for peritonetal dialysis comprises a double lumen structure with inner and outer tubes. The outer tube has a plurality of openings the inner tube being stretched in tension to prevent kinking of the catheter. The inner tube has a single outlet at the free end of the catheter. The tubing for the catheter is sufficiently flexible to permit the catheter to lie loosely and freely in the body cavity. Treatment fluids are delivered to the peritoneal cavity through the inner tube and removed via the outer tube.

Abstract: A method for treating porous polytetrafluoroethylene and other types of synthetic materials having low surface tension to render the material suitable for use in bonding to living tissue. The synthetic material is enveloped with a liquid of sufficiently low surface tension to permit the liquid to enter the pores of the material. The liquid has a sufficiently low gas content to enable the liquid to absorb or displace essentially all gas nuclei held in the pores of the material as the liquid fills essentially all pores. After the low surface tension liquid has permeated all pores of the porous material, such liquid is replaced with a solution compatible with the body fluid and in which proteins have a low solubility to render the material suitable for implant. When such material is placed in contact with exposed tissue, an immediate bond is formed which permits implanting the material without the need of sutures to hold the material in place.

Abstract: A method for isolating a cDNA specific for P-glycoprotein is disclosed. The P-glycoprotein is the determinant in the multidrug resistance phenotype exhibited by living cells. The nucleic acid equivalent of the cDNA may be cloned in a recombinant plasmid or phage. The cDNA may also be used as a probe in determining multidrug resistance in cells. The DNA molecules specific for the P-glycoprotein is in the form of a gene family where various members of the gene family are amplified to varying degrees in multidrug resistant cells from various sources.

Abstract: A process for preparing biological material for implant in mammal's cardiovascular system, respiratory system or soft tissue is disclosed. The process comprises:(1) isolating from a suitable donor a desired tissue sample of the biological material;(2) extracting the tissue sample with an hypotonic buffer solution at a mild alkaline pH, the buffer solution including active amounts of proteolytic inhibitors and antibiotics;(3) extracting the tissue sample with a buffered solution having a high concentration of salt, the solution being at a mild alkaline pH and including a non-ionic detergent with protease inhibitors and antibiotics;(4) subjecting tissue sample to enzymatic digestion in a buffered saline solution, the enzymes consisting of purified protease-free dioxyribonuclease and ribonuclease;(5) extracting the tissue sample with an anionic detergent at a mild alkaline pH; and(6) storing the tissue sample in physiologic buffered solutions.

Abstract: 1,10-phenanthroline-2,9-dicarboxylic acid and novel derivatives thereof such as 4,7-diphenyl-1,10-phenanthroline-2,9-dicarboxylic acid and 4,5,9,14-tetraaza-(1,2,3,4)-dibenzanthracene-3,5-dicarboxylic acid can be coupled to proteins through coupling groups to form conjugates which form higly fluorescent chelates in the presence of lanthanide salts. Derivatives of the above acids reactive toward proteins can be readily manufactured by relatively simple synthetic routes, and are useful in fluorescent immunoassay.

Abstract: A digoxin derivative/immunogenic protein conjugate is disclosed which has the carbohydrate moiety of digoxin intact. Antibodies raised against this conjugate show minimal cross-reactivity to digoxin metabolites enabling the use as an antibody in the diagnostic analysis for digoxin when measured in the presence of its metabolites found in serum isolated from a human.

Abstract: A specimen tray apparatus is disclosed primarily for use in cell culture studies. The apparatus includes a tray and a plurality of individual cells in the form of specimen vessels which can be removably located in the tray. A lid is also provided for the tray and is physically identical therewith. Each vessel has a cover which is received in an opening in the lid when the tray and lid are assembled, so that pressure sensitive tape can then be used to releasably secure the covers to the lid while allowing one or more of the covers to be released when appropriate by peeling back the tape.